The UK and US have finalized a landmark commercial pact that will guarantee no import taxes on UK drug products entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to raise funding on medicines through the National Health Service (NHS). This commitment secures that duties on these key exports will stay at nothing for a timeframe of the next three years.
This agreement follows earlier threats to hike import taxes on branded pharmaceutical products, with figures floated as high as one hundred percent.
"This arrangement with the United Kingdom reinforces the global environment for new treatments and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a statement said.
Economic Significance
Pharmaceuticals represent one of the Britain's most significant goods shipped to the US, which is clearly the largest market for major companies like GSK and AstraZeneca.
Trade data indicate that in the year leading up to September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This amount represented a significant portion of British export trade in that period.
"This guarantee secures work, boosts funding and facilitates the UK to become a international leader for medical research," the Business and Trade Secretary commented.
Detailed NHS Changes
The pact includes several specific changes from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to double overall public funding on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must return to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates exceeded twenty percent.
Recent Tensions
The pact comes amid a protracted dispute between the drug companies and the British authorities over medicine costs and approval rates.
The disagreement were heightened by assertions that American customers were charged several times more for the same drugs than patients in the other developed nations.
In recent months, several significant manufacturing plans in the UK have been delayed or abandoned, while major funding commitments have been announced toward American operations.
The Science Minister acknowledged that the NHS had to increase expenditure on treatments, noting that its budget allocation on drugs had decreased as a share of its resources over the last ten years.
